Tirzepatide is a prescription peptide that is used to help people lose weight. It is a dual GLP-1/GIP receptor agonist, which means that it mimics the effects of a naturally occurring hormone that helps to regulate appetite. Tirzepatide is injected once a week and can help people lose an average of 15-20% of their body weight over a 12-month period. It has been shown to outperform semaglutide in comparative studies.
Tirzepatide mimics the effects of a naturally occurring hormone called glucagon-like peptide-1 (GLP-1). GLP-1 is produced in the small intestine and helps to regulate appetite, digestion, and blood sugar levels.
Tirzepatide works by binding to GLP-1 receptors in the brain and gut. This binding causes a number of effects that lead to weight loss, including:
We slowly titrate up the medications based on the patients symptoms and will work with you to avoid negative effects.
Tirzepatide is not right for everyone. It is important to talk to your doctor before taking semaglutide if you have any of the following:
You will discuss your specific situation with our staff licensed physician and discuss your treatment plan.
All medications and supplies are included. No hidden fees.
Our medical staff are well trained and ready to answer any of your questions along the way.
You will be guided through your therapy and will be sent a progress form about once a month to document your progress. This can be done by mobile phone or computer. Our staff physician will check in with you on a scheduled basis and make changes to therapy along the way.
The ideal candidates for semaglutide are adults who are overweight or obese and have one or more of the following:
BPC-157 stands for Body Protection Compound 157, a peptide chain. It is considered synthetic, because the peptide sequence does not exist in nature. However, it is based on a protective compound present in the human stomach. BPC-157 works by triggering the formation of new blood vessels (angiogenesis). This may promote healing and induce faster regeneration of cells.
Several research studies note that BPC-157 aids in the treatment and tolerance with Semaglutide and Tirzepatide. Two of the most common adverse side effects of semaglutide are nausea and hypophagia. These reactions have been shown to be significantly reduced when employed in conjunction with BPC-157.
BPC-157 may provide many benefits for the body including:
The main difference between semaglutide and tirzepatide is that tirzepatide is a dual GLP-1/GIP receptor agonist, while semaglutide is a GLP-1 receptor agonist. GIP is another hormone that is released after eating and helps to regulate appetite and digestion. By targeting both GLP-1 and GIP receptors, tirzepatide may be more effective at reducing appetite and weight than semaglutide.
In clinical trials, tirzepatide was shown to be more effective than semaglutide at reducing weight and improving blood sugar control in people with obesity and type 2 diabetes. Tirzepatide was also shown to be better tolerated than semaglutide, with fewer side effects such as nausea and vomiting.
Tirzepatide is a newer medication than semaglutide.